Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Declines By 68.0%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 14,500 shares, a decrease of 68.0% from the March 31st total of 45,300 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 55,500 shares, the days-to-cover ratio is presently 0.3 days.

Alzamend Neuro Trading Down 1.3 %

ALZN traded down $0.01 during midday trading on Thursday, reaching $0.70. The company’s stock had a trading volume of 25,277 shares, compared to its average volume of 52,212. The firm has a market capitalization of $4.81 million, a price-to-earnings ratio of -0.74 and a beta of 0.02. Alzamend Neuro has a 1 year low of $0.65 and a 1 year high of $11.91. The stock’s 50-day moving average is $0.93 and its 200-day moving average is $1.23.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.38) earnings per share for the quarter.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.